Therapy News and Research

RSS

Blood gene expression profile identifies patients with elevated risk of cardiovascular death

A study of 338 patients with coronary artery disease has identified a gene expression profile associated with an elevated risk of cardiovascular death. Used with other indicators such as biochemical markers and family history, the profile - based on a simple blood test - may help identify patients who could benefit from personalized treatment and counseling designed to address risk factors.

30 May 2014

Findings have important implications for improving war wound healing

War wounds that heal successfully frequently contain different microbial species from those that heal poorly, according to a paper published ahead of print in the Journal of Clinical Microbiology.

30 May 2014

People with diabetes have about double risk of premature death

People with diabetes have about double the risk of premature death as people of the same age without diabetes.

30 May 2014

George Washington University launches advanced practice OTD degree program

The George Washington University (GW) School of Medicine and Health Sciences (SMHS) is pleased to announce an advanced practice Occupational Therapy Doctorate (OTD) degree program for practicing occupational therapists.

30 May 2014

New clinics vie to treat men

The New York Times examines a new marketing effort by hospitals to attract men. In the meantime, patient data sharing among medical professionals remains elusive.

30 May 2014

Study explores role of family factors in CPAP adherence in sleep apnea patients

A new study suggests that people with obstructive sleep apnea (OSA) who are single or have unsupportive family relationships may be less likely to adhere to continuous positive airway pressure (CPAP) therapy.

30 May 2014

Bipolar remission influenced by anxiety and OCD

Anxiety disorders and obsessive compulsive disorder may reduce the likelihood of achieving remission for patients with bipolar disorder, study findings indicate.

29 May 2014

Biomedical scientists explore mechanisms of novel treatments for HCV

As new treatments for hepatitis C virus (HCV) are approved, biomedical scientists are exploring their mechanisms and what they reveal about the virus.

29 May 2014

Allowing PTSD patients to choose their own treatment is less expensive, shows study

A cost-analysis of post-traumatic stress disorder treatments shows that letting patients choose their course of treatment - either psychotherapy or medication - is less expensive than assigning a treatment and provides a higher quality of life for patients.

29 May 2014

First Edition: May 29, 2014

Today's early morning highlights from the major news organizations, including articles on an inspector general's report on care at VA hospitals and growing pressure from some House Republicans to vote on an alternative to the Affordable Care Act.

29 May 2014

Synexus starts new state of art clinical trial centre in Bochum, Germany

On 28th May, 2014, Synexus officially opened a new state of the art clinical trial centre in Bochum, Germany.

From AES - Accelerated Enrollment Solutions 29 May 2014

ALOXI injection receives FDA approval for prevention of nausea, vomiting associated with cancer chemotherapy

Eisai Inc. and Helsinn Group today announced the Food and Drug Administration (FDA) approval of ALOXI (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy, in children aged 1 month to less than 17 years.

29 May 2014

Noninvasive laser therapy triggers stem cells to repair enamel of teeth

A Harvard-led team is the first to demonstrate the ability to use low-power light to trigger stem cells inside the body to regenerate tissue, an advance they reported in Science Translational Medicine.

29 May 2014

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

Trimel Pharmaceuticals Corporation announced today that the United States Food and Drug Administration (FDA) has approved Natesto (testosterone), formerly CompleoTRT, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

29 May 2014

Testing for STI co-infections may improve HIV prevention in Africa

To maximize HIV prevention efforts in South Africa and perhaps the broader region, public health officials should consider testing for other sexually transmitted infections when they test for HIV, according to a new paper in the journal Sexually Transmitted Infections.

29 May 2014

MedPage and CollabRx introduce CancerRx to help oncologists, pathologists

MedPage Today, a property of Everyday Health, Inc. and CollabRx, Inc. announced today the introduction of a new physician resource, CancerRx,™ an IOS application designed to help oncologists and pathologists navigate the complex landscape of oncology therapeutic options.

28 May 2014

Physical therapy may not benefit hip osteoarthritis

Researchers have questioned the value of physical therapy for painful hip osteoarthritis in a study published in JAMA.

28 May 2014

Patrys reports positive results from PAT-SM6 clinical trial in patients with multiple myeloma

Patrys Limited, a clinical stage biotechnology company, is pleased to announce the clinical results from a patient treated with PAT-SM6 in combination with other marketed multiple myeloma drugs.

28 May 2014

BioTime receives ISO 13485:2003 certification for development of BioTime HyStem hydrogels

BioTime, Inc. today announced that it has received ISO 13485:2003 certification from BSI (British Standards Institution) for design, development, manufacture, and distribution of BioTime HyStem® hydrogels for cell delivery applications.

28 May 2014

Transgenomic signs license with Dana-Farber to develop multiplexed ICE COLD-PCR technology

Transgenomic, Inc., a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that it has signed a license with the Dana-Farber Cancer Institute for worldwide rights to develop and commercialize multiplexed versions of its ICE COLD-PCRTM technology (MX ICE COLD-PCR).

28 May 2014